# The ADAMTS family: from extracellular matrix proteases to orchestrators of fibrosis

**Authors:** Yang Yuan, Peng Guo, Yajuan Song, Zhou Yu, Baoqiang Song

PMC · DOI: 10.1186/s12964-026-02743-0 · Cell Communication and Signaling : CCS · 2026-02-13

## TL;DR

This paper reviews how ADAMTS proteins influence fibrosis by modifying the extracellular matrix and regulating key fibrotic processes like TGF-β activation.

## Contribution

The paper highlights the dual regulatory roles of ADAMTS proteins in fibrosis and their potential as therapeutic targets.

## Key findings

- ADAMTS proteins modify ECM substrates and influence fibrosis through TGF-β activation and fibroblast phenotype switching.
- Individual ADAMTS members have tissue- and substrate-specific roles in fibrotic diseases.
- Translating ADAMTS-targeting therapies is challenging due to functional duality and substrate redundancy.

## Abstract

Fibrosis, a pathological process defined by excessive extracellular matrix (ECM) accumulation, contributes significantly to chronic organ failure worldwide. The ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family proteins are secreted, multi-domain matrix-associated zinc metalloendopeptidases, which have emerged as key regulators of fibrotic pathogenesis. While the ADAMTS proteins are well known for their ability to cleave ECM components such as collagens, proteoglycans, fibronectin, and fibrillins, their roles in fibrosis extend beyond conventional ECM modulators. Through precise proteolytic modification of these ECM substrates, ADAMTS members actively orchestrate upstream and core mechanisms driving fibrosis, notably TGF-β activation and fibroblast phenotype switching. Recent studies have uncovered tissue- and substrate-specific roles of individual ADAMTS members, highlighting their dual regulatory effects in fibrotic diseases and opening avenues for targeted therapeutic strategies. Despite promising preclinical results, translating ADAMTS-targeting therapies into clinical applications for fibrosis remains challenging due to their functional duality, substrate redundancy, and poorly characterized spatiotemporal specificity. This review comprehensively summarizes the proteolytic mechanisms of ADAMTS proteases toward ECM substrates, their multifaceted roles in fibrogenesis, and discusses their translational potential as therapeutic targets.

## Linked entities

- **Genes:** adamts (a disintegrin-like and metallopeptidase with thrombospondin type 1 motif) [NCBI Gene 8622232]
- **Proteins:** adamts (a disintegrin-like and metallopeptidase with thrombospondin type 1 motif), TGFB1 (transforming growth factor beta 1)

## Full-text entities

- **Genes:** TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}
- **Diseases:** Fibrosis (MESH:D005355), chronic organ failure (MESH:D009102), fibrotic diseases (MESH:D004194)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13005478/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13005478/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC13005478/full.md

---
Source: https://tomesphere.com/paper/PMC13005478